ASPEN
Brensocatib in Non-Cystic-Fibrosis Bronchiectasis
Doente / População Intervenção / Exposição Comparação Desfecho
In 1,721 patients with non-CF bronchiectasis and ≥2 exacerbations in the prior year, brensocatib 10 mg or 25 mg daily reduced annual exacerbation rate compared with placebo.
N
1721
Desenho
Multicentre phase-3 RCT
Desfecho
Annualised exacerbation rate over 52 weeks
Relevância
2
Resultado1.02 (10 mg) / 1.04 (25 mg) vs 1.29 (placebo); rate ratios 0.79 (p=0.004) and 0.81 (p=0.005). FEV1 decline reduced 38 mL/year (25 mg).
Chalmers JD, et al. N Engl J Med. 2025;392(16):1569-1581. 10.1056/NEJMoa2411664
Discussão e crítica
FDA approved August 2025 as Brinsupri — the first targeted therapy for non-CF bronchiectasis.